IBIO - iBio finds new panel of CD3 T-cell binding antibodies

2023-04-05 10:32:41 ET

• iBio ( NYSE: IBIO ) said it had discovered a panel of CD3 T-cell binding antibodies that kill tumor cells.
• T-cell are a new class of  antibodies designed to bind via CD3 and to tumor cells via tumor-specific antigens or tumor-associated antigens, inducing T-cell-mediated killing of tumor cells.
• The Company’s AI-based antibody, combined with mammalian display technology broadened the range of CD3 affinities, identified antibodies with cross-reactivity to non-human primates and increased the humanness of the antibody sequences, the company said.
• Early studies of CD3-based T-cell engagers showed promising clinical efficacy, but were hampered by severe dose-limiting toxicities.
• Press Release

For further details see: